COX-2 在浆液性卵巢癌中预后作用的Meta 分析
| 作者: |
1刘博,
2柳源,
3,4周建国
1 上海市浦东新区老港社区卫生服务中心全科，上海 201302 2 聊城市肿瘤医院医院感染管理科， 山东 聊城 252000 3 遵义医科大学附属医院，肿瘤医院胸部肿瘤科，贵州 遵义 563099 4 遵义医科大学第二附属医院，肿瘤医院胸部肿瘤科，贵州 遵义 563099 |
| 通讯: |
柳源
Email: zmc_liuy@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2019.06.024 |
| 基金: | 遵义医学院大学生创新创业训练项目 (ZY-201751044，ZYKY-20173830)；贵州省高校口腔重点实验室开放课题 (No. 6)；贵州省中医药管理局基金 (QZYY2017-113)。 |
摘要
目的：采用Meta分析方法系统性评价COX-2过表达与浆液性卵巢癌预后的相关性。方法：采用计算机检索中国知网(CNKI)、维普(VIP)、万方(WanFang Data)和PubMed等数据库及会议论文，搜集COX-2的表达与浆液性卵巢癌预后的队列研究，检索时限从建库至2018年11月1日。由2位研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后，采用R3.5.1软件进行分析。结果：共纳入7项研究。Meta分析结果显示：COX-2过表达的患者在总生存期(overall sur vival，OS；HR=1.57， 95%CI：1.26~1.95)、无病生存期(disease-free survival，DFS；HR=2.19，95%CI：1.30~3.68)等方面均差于COX-2低表达的患者。结论：COX-2过表达可能是浆液性卵巢癌患者预后不良的指标。
关键词：
COX-2；浆液性卵巢癌；预后作用；Meta分析；队列研究
COX-2 expression and prognosis of serous ovarian cancer patients: A Meta-analysis
CorrespondingAuthor: LIU Yuan Email: zmc_liuy@163.com
DOI: 10.3978/j.issn.2095-6959.2019.06.024
Foundation: This work was supported by Zunyi Medical University Training Program of Innovation and Entrepreneurship for Undergraduates (ZY-201751044, ZYKY-20173830)
Abstract
Objective: To systematically review the prognostic value of COX-2 expression in serous ovarian cancer. Methods: CNKI, VIP, WanFang Data, PubMed databases and Meeting Abstract were searched to collect on the CHM combined with chemotherapy for ovarian cancer from inception to November 1st, 2018. Two reviewers independently screened literature, extracted data and evaluated the risk bias of included studies. Meta-analysis was then performed using R 3.5.1 software. Results: Seven studies were included. Meta-analysis showed that patients with higher COX-2 expression had a poor OS (HR =1.57, 95% CI: 1.26–1.95) and DFS (HR =2.19, 95% CI: 1.30–3.68). Conclusion: The current evidence shows that COX-2 expression had the potential to be a prognostic marker of ovarian cancer.
Keywords：
serous ovarian cancer; COX-2; prognostic marker; Meta-analysis; cohort study